The Cooper Companies, Inc. (COO) is well-poised for growth, backed by strong prospects in its CooperVision (CVI) and CooperSurgical (CSI) business segments. Acquisitions boost the company's portfolio and buoy optimism. However, unfavorable currency movements and rising costs continue to hurt revenues and margins, respectively. Shares of this Zacks Rank #2 (Buy) company have risen 16.6% year to date compared with the industry's 0.3% growth. The S&P 500 Index has gained 20.6% in the said time frame. The Coope ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Eve ...

公司动态 - Crescendo任命Zack Urlocker为首席运营官(COO) 负责市场推广活动 向CEO Matt Price汇报 [1] - Zack Urlocker在快速构建优秀公司方面有20年成功经验 曾担任Zendesk COO(2022年以100亿美元退出) 与Matt Price密切合作 [3] - Zack Urlocker曾担任Gatsby CEO Duo Security COO(被思科以23.5亿美元收购) MySQL产品执行副总裁(被Sun Microsystems以10亿美元收购) [3] - Crescendo拥有强大的企业管理团队 包括执行主席Andy Lee 总裁Anand Chandrasekaran 首席产品官Tod Famous 首席技术官Slava Zhakov [4] 产品与技术 - Crescendo平台新增关键特性和功能 满足企业最苛刻需求 [1] - 平台旨在简化运营 提高客户满意度 赋能客服中心 将最新AI创新快速嵌入CX管理 结合人类领域专家 实现按结果定价 [2] - 平台允许人类领域专家管理更多事件 不断迭代改进平台 提供卓越客户体验 [2] - 平台提供强大且高度可扩展的增强AI解决方案 控制质量 自动化重复任务 保持客户期望的个性化 [5] - 平台包括覆盖所有主要渠道的AI助手 集成Zendesk Salesforce Hubspot等主要企业应用 符合SOC-2 Type II标准 通过HIPAA要求第三方测试 [6] 客户与市场 - 平台受到企业客户强烈需求 希望改善客户参与度 提高效率 [3] - 平台为早期客户带来显著成果 自2023年以来零客户停机 为消费电子公司RIO轻松处理客户参与度激增 解决90%售前查询和60%售后查询 提高CSAT [7] - 公司开发全球首个增强AI客户体验(CX)平台 结合AI和人类领域专业知识 为快速发展的数字原生企业提供结果驱动解决方案 [8] - 公司独特方法提供可扩展解决方案 优化前台和后台运营 帮助企业创造有意义 个性化的客户体验 [8]

BATAVIA, Ill., Sept. 19, 2024 (GLOBE NEWSWIRE) -- High Wire Networks, Inc. (OTCQB: HWNI), a leading global provider of managed cybersecurity, has appointed Edward Vasko, CISSP, as chief operations officer. He succeeds Stephen LaMarche, who will remain on the company's board of directors. Vasko will also continue to serve as chief executive officer of the company's Overwatch managed cybersecurity services division. Vasko brings to High Wire more than 33 years of accomplishment in the cybersecurity industry, ...

技术分析 - 公司近期50日简单移动平均线突破200日简单移动平均线，形成“金叉”，通常被视为看涨突破的重要信号 [1] - 金叉的形成分为三个阶段：股价下跌触底、短期均线突破长期均线、股价持续上涨 [1] - 公司股价在过去四周上涨18.7%，显示出强劲的上升势头 [1] 基本面分析 - 公司当前季度盈利前景乐观，过去60天内盈利预期有7次上调，且无下调 [2] - Zacks共识预期也有所上调，进一步强化了看涨逻辑 [2] 投资建议 - 鉴于公司技术面和盈利预期的双重利好，投资者可关注公司未来可能的进一步上涨 [2]

公司动态 - Ovid Therapeutics Inc 宣布晋升 Meg Alexander 为总裁兼首席运营官 (COO) [1] - Meg Alexander 将与公司领导团队合作，推进神经治疗药物的研发管道并制定执行公司的发展战略 [1] - Meg Alexander 将负责监督所有运营、研发、项目管理、投资者关系、商业战略、人力资源和公司事务，并向首席执行官 Jeremy Levin 汇报 [2] - 财务、法律和业务发展将继续由首席业务和财务官 Jeff Rona 负责 [2] 领导层背景 - Meg Alexander 自 2020 年加入 Ovid，曾担任首席战略官和首席企业事务官 [3] - 在 Ovid 任职期间，她支持公司重建专注于癫痫和罕见神经系统疾病的研发管道，领导运营执行并加强与关键利益相关者的关系 [3] - 在加入 Ovid 之前，Meg Alexander 拥有 20 年的职业生涯，曾为生物制药和财富 500 强公司制定战略，推动药物上市并降低风险 [4] - 她曾指导超过 25 种药物的上市，并为辉瑞、诺华、安进、强生等领先跨国公司制定重大计划 [4] - 她还创立并扩展了 Syneos Health 的声誉和风险管理业务 [4] 公司研发进展 - Ovid 正在推进一系列新型小分子候选药物，这些药物通过调节神经元过度兴奋的内在和外在因素来治疗癫痫和其他神经系统症状 [5] - 公司正在开发 OV888/GV101 胶囊，一种强效且高度选择性的 ROCK2 抑制剂，用于治疗脑部海绵状血管瘤和其他罕见中枢神经系统疾病 [5] - OV329 是一种 GABA-氨基转移酶抑制剂，用于治疗耐药性癫痫 [5] - OV350 是一种 KCC2 转运体的直接激活剂，用于治疗癫痫和其他精神疾病 [5] 公司愿景 - Ovid 致力于通过其研发管道改善受罕见癫痫和脑部疾病影响的患者的生活 [5] - 公司希望通过其科学、开发和交易专业知识，为患有难治性脑部疾病的患者创造价值并带来有意义的改变 [3]

公司荣誉与创新文化 - 公司被Fast Company评为“最佳创新工作场所”，表彰其在员工发展和归属感方面的文化，推动创新和新产品开发，旨在提高护理标准 [1] - 公司还入选2024年北美100家最具启发性的工作场所榜单，并在今年早些时候获得人权运动企业平等指数的满分100分 [3] 公司领导层观点 - 公司总裁兼首席执行官Al White表示，公司对自身和员工进行了重大投资，推动创新，最终改善患者治疗效果，并对这一荣誉感到自豪 [3] 公司概况 - 公司是一家全球领先的医疗设备公司，专注于通过两个业务部门CooperVision和CooperSurgical改善人们的生活 [4] - CooperVision是隐形眼镜行业的领导者，每天改善数百万人的视力 [4] - CooperSurgical是一家专注于生育和女性健康的公司，致力于在最重要的医疗时刻帮助女性、婴儿和家庭 [4] - 公司总部位于加利福尼亚州圣拉蒙，拥有超过15,000名员工，产品销往130多个国家 [4]

ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company's American Depositary Shares (ADSs), signaling their confidence in the company's growth and direction. On September 3 an ...

The Cooper Companies, Inc.'s (COO) business segment, CooperSurgical (CSI), announced the launch of a new inserter designed for single-hand placement of Paragard on Tuesday, which was recently approved by the FDA. The new single-hand inserter will likely simplify the placement process for healthcare providers, thus making Paragard a more accessible contraceptive choice for both providers and patients. Paragard, a hormone-free intrauterine device (IUD), prevents pregnancy for up to 10 years using copper as th ...

MONTEVIDEO, Uruguay, Sept. 06, 2024 (GLOBE NEWSWIRE) -- dLocal, a leading cross-border payment platform specializing in high-growth markets, announces the appointment of Carlos Menendez as Chief Operating Officer (COO), effective immediately. Jacobo Singer, who currently serves as COO and CoPresident, will continue to serve in both roles during a transition period until December 15, 2024, at which time he will step down from both roles. During this transition period, Carlos and Jacobo will work closely to e ...